MYC and neoplasm: In previous studies we showed that treatment with either the mutant p53 reactivating drugs, COTI-2 [18] or the MYC inhibitor, MYCi975 [24] resulted in decreased tumor cell proliferation and induction of apoptosis in mutant p53 breast cancer cell lines.